| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Menaquinone-7 (also known as Vitamin K2-7; Vitamin K2(35); Vitamin MK-7), a class of K2-vitamin homologs, is originally discovered as a potent anti-hemorrhagic factors. Menaquinone-7 is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins . Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS).
| ln Vitro |
In cultured media, menaquinone-7 (0.01-10 μM; 7 days) inhibits osteoclast-like cells [1]. In the presence of the phytoestrogen genistein (1, 10 μM), menaquinone-7 (10 μM) dramatically increases phosphorylated Menaquinone-7 (1, 10 μM) in MC3T3E1 cells and enhances the anabolic effect on femoral calcium levels [3].
|
|---|---|
| ln Vivo |
Depigmented bone loss is halted by menaquinone-7 (18.1 mg/100 g diet; in animal feed; 24 days) [5].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: Bone marrow cells (from 3-week-old male Wistar rats; stimulated by PTH/PGE2) Tested Concentrations: 0.01-10 µM Incubation Duration: 7 days Experimental Results: The number of TRACP-positive MNCs stimulated by PTH or PGE2 was significant. Dramatically reduces prostaglandin E2. |
| Animal Protocol |
Animal/Disease Models: Female Wistar rat (5 weeks old; ovariectomized (OVX) rat model)) [5].
Doses: 18.1 mg/100 g Dietary Route of Administration: animal feed; 24-day Experimental Results: Preventive effect on bone loss caused by OVX. |
| References |
[1]. Yamaguchi M, et al. Inhibitory effect of menaquinone-7 (vitamin K2) on osteoclast-like cell formation and osteoclastic bone resorption in rat bone tissues in vitro. Mol Cell Biochem. 2001 Dec;228(1-2):39-47.
[2]. Katsuyama H, et al. Menaquinone-7 regulates gene expression in osteoblastic MC3T3E1 cells. Int J Mol Med. 2007 Feb;19(2):279-84. [3]. Yamaguchi M, et al. Stimulatory effect of menaquinone-7 on bone formation in elderly female rat femoral tissues in vitro: prevention of bone deterioration with aging. Int J Mol Med. 2002 Dec;10(6):729-33. [4]. Peeters FECM, et al. Bicuspid Aortic Valve Stenosis and the Effect of Vitamin K2 on Calcification Using 18F-Sodium Fluoride Positron Emission Tomography/Magnetic Resonance: The BASIK2 Rationale and Trial Design. Nutrients. 2018 Mar 21;10(4):386. [5]. Yamaguchi M, Taguchi H, Gao YH, Igarashi A, Tsukamoto Y. Effect of vitamin K2 (menaquinone-7) in fermented soybean (natto) on bone loss in ovariectomized rats. J Bone Miner Metab. 1999;17(1):23-9. |
| Molecular Formula |
C46H64O2
|
|---|---|
| Molecular Weight |
649.00
|
| CAS # |
2124-57-4
|
| Related CAS # |
Menaquinone-7-13C6;Menaquinone-7-d7;1233937-31-9
|
| SMILES |
O=C1C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)\C)=C(C)C(C2=C1C=CC=C2)=O
|
| Synonyms |
Vitamin K2-7; Vitamin K2(35); Vitamin MK-7
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~7.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 0.54 mg/mL (0.83 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.4 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.54 mg/mL (0.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.4 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5408 mL | 7.7042 mL | 15.4083 mL | |
| 5 mM | 0.3082 mL | 1.5408 mL | 3.0817 mL | |
| 10 mM | 0.1541 mL | 0.7704 mL | 1.5408 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA